期刊文献+

血浆PAI-1和TAFI的变化对STEMI患者静脉溶栓治疗后血管再通的预测价值 被引量:1

The tendency of PAI-1 and TAFI levels in STEMI patients after thrombolytic treatment and its predictive value to restoration of coronary perfusion
原文传递
导出
摘要 目的通过检测急性心肌梗死(AMI)患者静脉溶栓前、后2小时内血浆凝血酶激活的纤溶抑制物(TAFI)和纤溶酶原激活物抑制剂-1(PAI—1)的含量,探讨两者的变化是否对溶栓后血管再通具有预测价值。方法2007年1月至2009年3月期间收集广州医学院第二附属医院急诊科16例急性ST段抬高心肌梗死(STEMI)患者溶栓前、后0.5,1,1.5,2h的血浆标本,并以16名健康人作为健康对照组,用ELISA法测定血浆中TAFI和PAI-1的含量。结果(1)与健康对照组相比,STEMI患者溶栓前的血浆PAI-1水平显著升高(P〈0.01);而TAFI活性与对照组相比差异无统计学意义。(2)与溶栓前相比,溶栓后0.5,1,1.5,2h的血浆TAFI活性较溶栓前比较,差异无统计学意义(P〉0.05);溶栓后1.5,2h的血浆PAI-1显著升高(P〈0.01)。(3)溶栓后2h冠脉未通组PAI-1水平显著高于再通组(P〈0.05);而冠脉未通组和再通组TAFI活性差异无统计学意义(P〉0.05)。结论升高的血浆PAI-1在溶栓后2h下降可能对溶栓后血管再通具预测价值,TAFI对血管再通不具预测价值。 Objective To observe the tendency of the plasma concentration of plasminogen activator inhibitor type-1 (PAI-1) and thrombin activatable fibrinolysis inhibitor (TAFI) before and after thrombolytic treatment of acute ST elevation myocardial infarction (STEMI) and to explore their recanalization predictive value of PAI-1 and TAFI for acute myocardial infarction patients with thrombolytic treatment. Methods Sixty patients, who received thromobolytie treatment from January 2007 to March 2009, were prospectively recruited. The blood sample were collected within 2 hours of thromobolytic treatment ( 0, 0. 5 h, 1 h, 1.5 h and 2 h). The plasma concentration of TAFI and PAI-1 were test by ELISA. 16 healthy people were recruited as control group. Results The plasma levels of PAI-1 in STEMI patients before thrombolytie treatment were higher than those of Control group ( P 〈 0. 01 ) , however the same significant change of TAFI level was not seen. The levels of TAFI were no significant difference before and after thrombolytic therapy during whole observation periods. However, the level of PAI-1 increased at 1.5 h and 2 h after thrombolytic therapy (P 〈 0. 01 ). The plasma PAI-1 levels of no - revascularigation group at 2 h after thrombolytie therapy were significant higher than that in revascularization group ( P 〈 0.05 ). The levels of TAFI were not significantly different between two groups ( P 〉 0. 05 ). Conclusions The decrease of plasma PAI-1 from high level within 2 hours after thrombolysis treament may be exploring the predictive value for revaseularization. The tendency of TAFI can' t forecast the result of revascularization.
出处 《中华急诊医学杂志》 CAS CSCD 北大核心 2011年第12期1321-1324,共4页 Chinese Journal of Emergency Medicine
基金 广东省社会发展领域科技计划项目(20098030801366) 广州市卫生局科研基金资助课题(2008-YB-175)
关键词 急性心肌梗死 ST段抬高心肌梗死 溶栓治疗 重组组织型纤溶酶原激活剂 凝血酶激活的纤溶抑制物 纤溶酶原激活物抑制剂一l 血管再通 预测价值 Acute myocardial infarction STEMI Thrombolystic therapy rt-PA TAFI PAl-1 R ecanalization / revaseularization predictive value
  • 相关文献

参考文献8

二级参考文献39

  • 1陈树涛,王林,李广平,丛洪良,张梅,徐延敏,王伟,张承宗,黄体钢.注射用重组瑞替普酶治疗急性心肌梗死的疗效评价[J].中国心血管杂志,2005,10(5):363-365. 被引量:15
  • 2杨勇填,李炳流,江慧琳,林珮仪,李燕屏,陈晓辉.重组型纤溶酶原激活剂与尿激酶在急性心肌梗死溶栓中的比较[J].中国急救医学,2006,26(11):814-816. 被引量:4
  • 3[1]Chetaille P,Alessi MC,Kouassi D,et al. Plasma TAFI Antigen Variations in Healthy Subjects [J]. Thromb Haemost,2000; 83: 902~ 905.
  • 4[2]Zhao L,Morser J,Bajzar L,et al. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms[J]. Thromb Haemost,1998;80(6) :949~955.
  • 5[3]Mosnier LO,Von der Borne PAK,Meijers JCM,et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation [J]. Thromb Haemost, 1998; 80: 829~ 835.
  • 6[4]Schneider M,Boffa M,Stewart R,Rahman ML,Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr 325 and Ile 325)differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme [J]. J Biol Chem, 2002 ; 277: 9944~ 9951.
  • 7Luttun A, Lupu F,Storkebaum E,et al. Laok of plasminogen activator inhibitor-promotes growth and abnormal matrix remodeling of advanced atherosclecotic plaques in apoliprotein E-deficient mice[J].Arterioscler Thromb Vasc Biol,2002,22(3):499.
  • 8Ploplis VA,Cornelissen L,Sandoval-cooper MJ,et al. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1[J].Am J Pathol, 2001,158(1):107.
  • 9Banff C,Mussoni L,Tremoli E.PAI-1 the primary plasmatic inhibitor of fibrinolysis.physiopathologic role and molecular mechanisms[J].Minerva Endocrinol,2002,27(3): 181.
  • 10Huber K, Christ G.Plasminogen activator inhibitor type-1 in cardiovascular disease.disease. Status report 2001[J].Thromb Res,2001,103(11):7.

共引文献5023

同被引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部